louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01417468: How Well do Patients With Traumatic Brain Injury Learn New Material Using Learning Styles in Online Science Classrooms?
Official title: Instructional Design Strategies to Support Adult Patients/Students (Civilian & Military) With Traumatic Brain Injury (TBI).
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Brain Injuries
Brain Injuries, Traumatic
Injury, Brain, Traumatic
Traumatic Brain Injury
Brain Injury, Chronic
Keywords: Cognitive Rehabilitation
Learning Styles
Learning Modes
Learning Modalities
Multiple Intelligences
Educational Intervention
Instructional Design
Lead sponsor: Center for Vision Development, New Market, Maryland
Sponsor class: OTHER
First posted: 2011-08-16
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine whether learning styles are effective in the treatment of traumatic brain injury (TBI) in an educational environment.

Detailed description: The purpose of this study is to determine the learning outcome and effectiveness of instructional design strategy using Canfield's learning styles and Gardner's Multiple Intelligences to accommodate TBI-induced cognitive impairments in an online science learning environment.

Eligibility criteria: Inclusion Criteria:

1. People who have been diagnosed with Mild Traumatic Brain Injury (TBI).
2. People who are able to understand and sign an informed consent form.
3. People who have no other known neurological disorder (e.g. aphasia, stroke).
4. All participants must be 18-50 years old.
5. Be able to speak and understand English, and
6. Have use of a computer (Mac or Windows) and internet (www) access.

Exclusion Criteria:

1. Don't meet the inclusion Criteria
2. Other known neurological disorder (e.g. aphasia, stroke).

Primary outcomes:
measure: Learning Effectiveness
timeFrame: 3 Months
Secondary outcomes:
Other outcomes:
Locations:
city: New Market
country: United States
facility: Center for Vision Development - (Research is being conducted online)
state: Maryland
Study officials:
affiliation: Capella University
name: Mark C. Pettinato, M.S.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Canfield, A. (1980). Learning styles inventory manual. Ann Arbor, MI: Humanics Media. Pashler, H.; McDaniel, M.; Rohrer, D.; Bjork, R. (2009).
Clinical trial NCT05145868: Just-In-Time Intervention to Reduce Alcohol-Facilitated Intimate Partner Violence Perpetration
Official title: Evaluation and Optimization of a Just-in-Time Messaging Intervention to Reduce Alcohol-Facilitated Intimate Partner Violence Perpetration Among At-Risk Young Adult Men and Women
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Alcohol Drinking
Aggression
Emotion Regulation
Lead sponsor: Georgia State University
Sponsor class: OTHER
First posted: 2021-12-06
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Acute alcohol intoxication is a robust predictor of intimate partner violence (IPV) perpetration for young adult men and women; therefore, interventions delivered proximally to drinking episodes - a period of high risk - are needed to reduce alcohol-facilitated IPV. This project seeks to improve public health by delivering a just-in-time text messaging intervention proximally to drinking episodes and evaluating the impact of the intervention on alcohol-facilitated IPV in a sample of at-risk young adult men and women. Additionally, through an innovative design this project is poised to answer these important questions: whether receiving a message, when, for whom, what type, and under what conditions this just-in-time messaging intervention leads to reductions in alcohol use and IPV perpetration.


Eligibility criteria: Inclusion Criteria:

* 18-30 years old
* Consumed alcohol an average of 2 times per week in last 3 months
* At least two instances of heavy episodic drinking in last month
* Currently in a romantic relationship
* History of IPV perpetration within last 3 months
* Willing to provide cell phone number and carrier and receive text messages for 30 days

Exclusion Criteria:

* None

Primary outcomes:
measure: Alcohol Use
timeFrame: 30 days
measure: Alcohol Use
timeFrame: 1-month follow-up
measure: Alcohol Use
timeFrame: 3-month follow-up
measure: Alcohol Use
timeFrame: 6-month follow-up
measure: Intimate Partner Violence
timeFrame: 30 days
measure: Intimate Partner Violence
timeFrame: 1-month follow-up
measure: Intimate Partner Violence
timeFrame: 3-month follow-up
measure: Intimate Partner Violence
timeFrame: 6-month follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Georgia State University
state: Georgia
Study officials:
affiliation: Georgia State University
name: Cynthia Stappenbeck, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04703868: A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects
Official title: A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Gastroesophageal Reflux Disease
Lead sponsor: Yungjin Pharm. Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Seoul National University Hospital
First posted: 2021-01-11
Enrollment: 88
Sex: ALL
Minimum age (years): 19
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: A study to compare the safety, pharmacokinetics and pharmacodynamics of YPI 011 to Rabeprazole in healthy adult subjects

Detailed description: This study is to compare the safety, pharmacokinetics and pharmacodynamics of YPI 011 to Rabeprazole in healthy adult subjects

Eligibility criteria: Inclusion Criteria:

* Age 19\~55 years in healthy volunteers
* BMI is more than 18.0 kg/m\^2 , no more than 28.0 kg/m\^2
* Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing

Exclusion Criteria:

* Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system
* Subjects who were judged ineligible by the investigator

Primary outcomes:
measure: Integrated gastric acidity
timeFrame: From Day 1 up to Day 28
measure: AUCt,ss
timeFrame: From Day 1 up to Day 29
Secondary outcomes:
measure: Percent decrease from baseline in integrated gastric acidity for 24 hour interval after 1 st dose
timeFrame: 24 hours
measure: Percent of time with gastric pH>4 for 24 hour interval after 1st and 7th dose
timeFrame: From Day 1 up to Day 28
measure: Mean and median gastric pH after 1st and 7th dose
timeFrame: From Day 1 up to Day 28
measure: AUCτ
timeFrame: From Day 1 up to Day 29
measure: Cmax
timeFrame: From Day 1 up to Day 29
measure: Tmax
timeFrame: From Day 1 up to Day 29
measure: t1/2
timeFrame: From Day 1 up to Day 29
measure: CL/F
timeFrame: From Day 1 up to Day 29
measure: Vz/F
timeFrame: From Day 1 up to Day 29
measure: Cmin,ss,
timeFrame: From Day 1 up to Day 29
measure: Cmax,ss
timeFrame: From Day 1 up to Day 29
measure: Cav,ss,
timeFrame: From Day 1 up to Day 29
measure: Tmax,ss
timeFrame: From Day 1 up to Day 29
measure: t1/2,ss
timeFrame: From Day 1 up to Day 29
measure: CLss/F
timeFrame: From Day 1 up to Day 29
measure: Vss/F
timeFrame: From Day 1 up to Day 29
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
state: Daehak-ro Jongno-gu
Study officials:
affiliation: Seoul National University Hospital
name: Seunghwan Lee, M.D., Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06980168: Kabat Technique vs Neural Mobilization in Bells Palsy
Official title: Effectiveness of Kabat Technique Verses Neural Mobilization With Facial Exercises in Bells Palsy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Bell&#39;s Palsy
Keywords: kabat technique
House brackman scale
Neural mobilization
Bells palsy
Facial disability index
Lead sponsor: Elite College of Management Sciences, Gujranwala, Pakistan
Sponsor class: OTHER
First posted: 2025-05-20
Enrollment: 28
Sex: ALL
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to compare the effect of kabat technique and neural mobilization with facial exercises in improving functional outcomes of patient with bells palsy

Detailed description: Bells palsy is seventh cranial nerve disorder which causes muscle weaknesss on one side of the face .Various approaches are applied to restore facial function but this study aims to distinguish kabat technique and neural mobilization .This study will assess and compare the functional recovery of facial muscles and improvemrnt in facial symmetry .This will help determine which intervention is more effective .

Eligibility criteria: Inclusion Criteria:

* patient diagnosed with bells palsy in less than 2 weeks

Exclusion Criteria:

* head injuries recent surgeries psycological issues multiple sclerosis

Primary outcomes:
measure: House-Brackman scale
timeFrame: 3rd week
Secondary outcomes:
measure: Facial disability index
timeFrame: 3rd week
Other outcomes:
Locations:
city: Gujranwala
country: Pakistan
facility: Al raee hospital gujranwala ,Sardar yasin malik hospital, Rahat abdul gaffar medical complex
state: Punjab
Study officials:
affiliation: Elite College of Management Science
name: Mahnoor Hassan, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03020368: Effectiveness and Safety of Breeded Leech for Symptomatic Primary Arthrosis of the First Carpometacarpal Joint
Official title: Effectiveness and Safety of Breeded Leech "Medileech" by BioRepro GmbH for Symptomatic Primary Arthrosis of the First Carpometacarpal Joint: a Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Rhizarthrosis
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2017-01-13
Enrollment: 52
Sex: ALL
Minimum age (years): 35
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this trial the investigators want to prove the efficacy and safety of a one-time topical leech application at patients with symptomatic primary arthrosis of the first carpometacarpal joint in comparison to the standard therapy with topical diclofenac.


Eligibility criteria: Inclusion Criteria:

* Male and female patients aged 35 to 85 years
* Pain intensity in the region of the thumb base in pain phases ≥ 40 mm on the VAS of 0 to 100 mm (relative to the last 24 hours)
* Complaints for at least 3 months
* X-ray Stadium Eaton I-IV at least once secured

Exclusion Criteria:

* Anticoagulation (Marcumar, Heparin)
* Haemophilia, V. Willebrandt Jürgens syndrome, thrombocytopathy and other blood anomalies
* Combination therapy of ASA and thienopyridines
* Pain medication with opioid analgesics
* Systemic medication with corticoids or immunosuppressants
* Intraarterticular injections or RSO within the last 3 months
* Past or planned surgery on the affected joint in the next 2 months
* Pregnancy, lactation
* Insulin-dependent type I diabetes mellitus
* Acute psychotic disorders
* Severe comorbidity

Primary outcomes:
measure: Disabilities of the Arm, Shoulder and Hand (DASH)
timeFrame: Change after 28 and 56 days
Secondary outcomes:
measure: Visual analog scale (VAS)
timeFrame: Change after 7, 28 and 56 days
measure: Medication on demand
timeFrame: Documentation between baseline and day 56
Other outcomes:
measure: Expectation
timeFrame: Baseline
measure: Overall assessment of efficacy and tolerability
timeFrame: Day 56
Locations:
city: Berlin
country: Germany
facility: Hochschulambulanz für Naturheilkunde der Charité-Universitätsmedizin Berlin am Immanuel-Krankenhaus
Study officials:
affiliation: Charite Centrum Epidemiologie und Gesundheitsökonomie, CC1: Gesundheitswissenschaften
name: Andreas Michalsen, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00471068: Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension
Official title: Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Open-angle Glaucoma
Ocular Hypertension
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2007-05-09
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the efficacy and safety in patients treated with travoprost versus dorzolamide/timolol maleate combination in patients with open-angle glaucoma or ocular hypertension


Eligibility criteria: Inclusion Criteria:

* Patient with open-angle glaucoma or ocular hypertension

Exclusion Criteria:

* By Age

Primary outcomes:
measure: Intaocular Pressure (IOP) Mean Change After 6 Weeks of Treatment
timeFrame: At week 0 and week 6
Secondary outcomes:
Other outcomes:
Locations:
city: Coimbra
country: Portugal
facility: Coimbra
Study officials:
affiliation: Alcon Research
name: Anna Grau
role: STUDY_DIRECTOR
References:
Clinical trial NCT03038568: Assessing How Normal Variations in CT Scanning Affects Its Interpretation
Official title: Stability of Radiomic Features for Abdominal Tumors on Contrast Enhanced CT
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Colorectal Cancer Metastatic
Keywords: colorectal liver metastases
CT scan
17-010
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
Collaborators: name: Kingston Health Sciences Centre
First posted: 2017-01-31
Enrollment: 169
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who undergo contrast enhanced CT scanning for colorectal liver metastases will be consented for one additional CT abdomen phase during the same imaging session.

Brief summary: The purpose of the study is to see how measurements of tumor differences vary with slight changes in CT scan parameters. Reproducible radiomic features can be extracted for abdominal tumors, and specifically colorectal liver metastases, imaged with clinical CT scanners even in the setting of variable scan parameters and variable contrast timing. Participants will be consented to undergo an additional CT of their abdomen.


Eligibility criteria: Inclusion Criteria:

* Patients ≥ 18 years of age on the day of signed informed consent
* Patients scheduled and approved for contrast enhanced CT that includes imaging of the abdomen and pelvis following the Department of Radiology standard of care protocol as per local institutional guidelines
* Patients with measurable colorectal liver metastases on prior imaging, with at least one tumor greater than 2.0 cm in axial maximal diameter

Exclusion Criteria:

* Patient who is pregnant and/or lactating
* Patient scheduled for CT that includes the abdomen with a multiphasic contrast enhanced protocol (e.g. Triple Phase or Quadruple Phase Liver CT)
* Patient who require reduced intravenous contrast dose based on the Department of Radiology contrast policy as per local institutional guidelines
* Any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or follow up procedures

Primary outcomes:
measure: assess the stability (reproducibility) of radiomic measurements obtained from repeat abdominal CT scans
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Houston
country: United States
facility: MD Anderson Cancer Center, Texas (Data collection only)
state: Texas
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Kinh Gian Richard Do, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01245868: Spinal Anaesthesia for Knee Arthroscopy: Does Lignocaine Shorten the Effect of Bupivacaine
Official title: Spinal Anaesthesia for Knee Arthroscopy: Does Lignocaine Shorten the Effect of Bupivacaine?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Spinal Anesthesia
Keywords: Spinal anaesthesia
Bupivacaine
Lidocaine
Duration of blockade
Lead sponsor: Frederikssunds Hospital, Denmark
Sponsor class: OTHER
First posted: 2010-11-23
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to investigate if a small amount of lignocaine added to bupivacaine for spinal anesthesia to patients planned for arthroscopic knee surgery, can shorten the duration of the sensoric and the motoric blockade.


Eligibility criteria: Inclusion Criteria:

* The patient want spinal anaesthesia
* No contradictions against spinal anaesthesia
* Healthy people (ASA-score 1 or 2)
* Body mass index \< 35 and between 155 and 190 cm

Exclusion Criteria:

* Known allergic reactions to planned drugs
* Neurologic disturbances
* Diabetes

Primary outcomes:
measure: Duration of spinal blockade
timeFrame: Repeating monitoring every 15 minutes after applying the blockade, up to 360 minutes.
Secondary outcomes:
measure: Time to fulfillment of discharge criteria from the hospital.
timeFrame: Evaluated every 15 minutes after the operation up to 360 minutes. On average 200 to 300 minutes.
Other outcomes:
Locations:
city: Frederikssund
country: Denmark
facility: Dep. of anesthesiology, Hospital of Frederikssund
city: Frederikssund
country: Denmark
facility: Jon Jacobsen
Study officials:
affiliation: Frederikssunds Hospital, Denmark
name: Jon Jacobsen, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06178068: Comparison of Bronchodilator Treatment Practices in Group E COPD Patients
Official title: Comparison of Bronchodilator Treatment Practices in Group E COPD Patients
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: COPD Exacerbation Acute
Lead sponsor: Ataturk University
Sponsor class: OTHER
First posted: 2023-12-20
Enrollment: 39
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: COPD is a heterogeneous condition caused by airway (bronchitis/bronchiolitis) or alveolar (emphysema) abnormality, changes with chronic respiratory changes (dyspnea, dyspnoea, phlegm). It is characterized by persistent and frequently progressive airway obstruction. In COPD, which progresses with high mortality, non-pharmacological treatments are applied, as well as pharmacological treatments. They have an essential place in slowing down the progressive course of this treatment. However, despite the treatment administered to COPD patients, outdoor weather conditions, improper use of inhaler treatments, or comorbidities may cause acute exacerbation of COPD.

Dry air nebulizer devices use dry air from the central system in hospitals. This system, which converts bronchodilator drugs into nebulizers by creating high currents, works like classical nebulizers without an electrical system and can have a higher flow rate than jet nebulizer devices. This procedure, which can be applied to COPD patients without giving high-flow oxygen, prevents carbon dioxide retention. There is no study in the literature comparing the bronchodilator effectiveness of dry air, classical nebulizer, and jet nebulizer, and the investigators aimed to compare the efficacy of these three treatment modalities in our study.


Eligibility criteria: Inclusion Criteria:

* Group E COPD patients

Exclusion Criteria:

* Recent MI
* Pulmonary embolism
* Cerebral aneurysm
* Active hemoptysis
* Pneumothorax
* Nausea, vomiting
* Recent thorax, abdominal, and eye surgery were identified in the patients before the pulmonary function test and were not included in the study.
* Mental retardation
* Pneumonia with acute exacerbation of COPD
* Patients with pulmonary edema due to congestive heart failure
* Patients with interstitial lung disease along with COPD

Primary outcomes:
measure: Evaluation of the change in respiratory function test parameters after 5 days of nebulizer treatment applications.randomization on respiratory function tests
timeFrame: 5 days
measure: Evaluation of the change in arterial blood gas parameters after 5 days of nebulizer treatment applications.randomization on respiratory function tests
timeFrame: 5 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06763068: Skeletal Muscle Mass Used to Assess Frailty in Older Gastric Cancer Patients
Official title: BIA-measured Skeletal Muscle Mass Used to Assess Frailty in Older Gastric Cancer Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastric (Stomach) Cancer
Frailty
Sarcopenia
Malnutrition Elderly
Keywords: gastric cancer
skeletal muscle mass
frailty
sarcopenia
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
First posted: 2025-01-08
Enrollment: 575
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Convenience sampling method was used to select older people with gastric cancer who attended a tertiary care hospital in China from March 2021 to December 2022 as the study objects

Brief summary: The primary aim of this study was to quantify the diagnosis of pre-surgical skeletal muscle mass in elderly gastric cancer patients and to analyse its correlation with frailty. The second aim was to investigate whether skeletal muscle mass, or sarcopenia, is associated with mobility and nutritional status, and anxiety and depression. The main questions it aims to answer are whether skeletal muscle mass is significantly associated with frailty and whether it can be used as a brief screening tool for preoperative frailty.


Eligibility criteria: Inclusion Criteria:

* diagnosed with gastric cancer by endoscopy or pathology; age \>60 years old; radical gastrectomy was proposed; be able to communicate simply in writing and verbal.

Exclusion Criteria:

* received preoperative radiotherapy or chemotherapy; combined with other sites of malignant tumors; combined with severe heart, liver, lung and renal insufficiency; recent using hormones, immunosuppressants; with physical disabilities.

Primary outcomes:
measure: Skeletal muscle mass
timeFrame: Within 24 hours of admission
measure: frailty
timeFrame: Within 24 hours of admission and discharge
Secondary outcomes:
measure: Nutritional Status
timeFrame: Within 24 hours of admission and discharge
measure: anxiety and depression
timeFrame: Within 24 hours of admission and discharge
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Nanjing Medical University
state: Jiangsu
Study officials:
References: